A follow-up Phase II open-label study to evaluate the long-term safety and efficacy profile of ABX464 given at 25 mg once daily in subjects with Moderate to Severe Active Ulcerative Colitis
Latest Information Update: 10 Oct 2024
Price :
$35 *
At a glance
- Drugs Obefazimod (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Abivax
- 03 Oct 2024 According to an Abivax media release, the company look forward to presenting data from this study at an upcoming medical meeting.
- 03 Oct 2024 Results presented in an Abivax Media Release.
- 15 Jul 2024 According to an Abivax media release, anticipated trial data read-out after one and two years of continued treatment with a reduced dose of obefazimod at 25 mg in Q3 2024.